Skip to search formSkip to main contentSkip to account menu

OSI-7836

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

4'-thio-arabinofuranosylcytosine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada…
Purpose: To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile… 
2006
2006
A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies
Purpose: To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in… 
2006
2006
Safety Assessment of 4′-Thio-β-d-Arabinofuranosylcytosine in the Beagle Dog Suggests a Drug-Induced Centrally Mediated Effect on the Hypothalamic-Pituitary-Adrenal Axis
4′-Thio-β-d-arabinofuranosylcytosine (OSI-7836) is a nucleoside analogue with structural similarity to gemcitabine and cytarabine… 
2006
2006
Study of a NewNucleosideAnalogue , OSI-7836 , Using TwoAdministration Schedules in Patientswith Advanced SolidMalignancies
Purpose:To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in… 
2005
2005
Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors
OSI-7836 (4′-thio-β-d-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of… 
2004
2004
Polymerization of the triphosphates of ara-C, 2’,2’-difluorodeoxycytidine and OSI-7836 (4’-thio-ara-C, S-ara-C) by human DNA polymerase α and DNA primase
Proc Amer Assoc Cancer Res, Volume 45, 2004 2973 OSI-7836, a nucleoside analog in development for the treatment of solid… 
2003
2003
544 A phase I trial of the novel nucleoside analog osi-7836 given on days 1 and 8 every 3 weeks: ncic ctg ind. 147
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)